Evidence map›Paper›PMID 38535924›Full record

ArticleToxics2024

Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study.

Fernando Rodríguez de Fonseca, Francisco Medina-Paz, Mira Sapozhnikov, Isaac Hurtado-Guerrero, Leticia Rubio, Stella Martín-de-Las-Heras, Nerea Requena-Ocaña, María Flores-López, María Del Mar Fernández-Arjona, Patricia Rivera and 4 more

Open access · goldAbstract read
In one paragraph

Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Fernando Rodríguez de FonsecaInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0002-4516-5795
Francisco Medina-PazDepartment of Chemistry and Environmental Sciences, New Jersey Institute of Technology, Tiernan Hall 365, Newark, NJ 07102, USA.ORCID 0000-0002-8714-2962
Mira SapozhnikovDepartment of Chemistry and Environmental Sciences, New Jersey Institute of Technology, Tiernan Hall 365, Newark, NJ 07102, USA.ORCID 0000-0003-2560-7178
Isaac Hurtado-GuerreroInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.
Leticia RubioInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0002-8233-624X
Stella Martín-de-Las-HerasInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0002-1554-951X
Nerea Requena-OcañaInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.
María Flores-LópezInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0003-3489-1465
María Del Mar Fernández-ArjonaInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.
Patricia RiveraInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.
Antonia SerranoInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.
Pedro SerranoInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0002-3414-2707
Sara C ZapicoDepartment of Chemistry and Environmental Sciences, New Jersey Institute of Technology, Tiernan Hall 365, Newark, NJ 07102, USA.ORCID 0000-0002-3605-5690
Juan SuárezInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 Málaga, Spain.ORCID 0000-0001-5254-9802
Hospital Regional Universitario de Málaga · ESInstituto de Investigación Biomédica de Málaga · ESNew Jersey Institute of Technology · USSmithsonian Institution · US

Funding

Consejería de Salud y Familias RIC-0111-2019Consejería de Universidad, Investigación e Innovación PI21/00291Fulbright Visiting Scholar Program, United States Department of State and Ministerio de Educa-ción y Formación Profesional CAS21/00169Fulbright Visiting Scholar Program, United States Department of State and Ministerio de Educa-ción y Formación Profesional PRX21/00439Instituto de Salud Carlos III CP19/00068Instituto de Salud Carlos III RD16/0017/000Instituto de Salud Carlos III RD21/0009/0003Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU PI20/01399Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU) PI19/01577Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU) PI22/00427Ministerio de Universidades María ZambranoMinistry of Health PNSD 2019/040Ministry of Health PNSD 2020/048Ministry of Health PNSD 2022/020Universidad de Málaga B1-2022_35
6 · The paper itself

Abstract

Alcohol use disorder (AUD) is a major component in the etiology of cognitive decline and dementia. Underlying mechanisms by which long-term alcohol abuse causes cognitive dysfunction include excessive oxidative stress and inflammation in the brain, activated by increased reactive oxygen/nitrogen species (ROS/RNS), advanced glycation end-products (AGEs) and high-mobility group box 1 protein (HMGB1). In a pilot study, we examine the potential clinical value of circulating biomarkers of oxidative stress including ROS/RNS, HMGB1, the soluble receptor for AGE (sRAGE), the brain biomarker of aging apolipoprotein D (ApoD), and the antioxidant regulator nuclear factor erythroid 2-related factor 2 (NRF2) as predictive indices for cognitive impairment (CI) in abstinent patients with AUD (

Indexed as

addictionadvanced glycation end-productsalcohol use disorderAlzheimer’s diseaseapolipoprotein Dcognitive impairmentdementiaHMGB1oxidative stress

Identifiers

PMID38535924
PMCPMC10974976
OpenAlexW4392293739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.